
For decades clinicians, have been frustrated by the inability to successfully detoxify opiate addicted patients because opiate-based detoxification, one of the most effective means to achieving that goal, has been unavailable outside the very restrictive confines of narcotic treatment programs. Bup/Nx shows promise as an effective aid for opiate detoxification; however, little data have been generated for the shorter-term use of Bup/Nx for this indication. Because the diversity of clinics in the CTN provides an unparalleled opportunity to conduct such a clinical endeavor, the utility of buprenorphine/naloxone in short term (13 day) detoxification versus clonidine in an outpatient setting was tested in the CTN.
Ling, W., et al. (2005). A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings for the National Institute on Drug Abuse Clinical Trials Network. Addiction 100:1090-1110.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1480367/
Principal Investigator(s):
Walter Ling, M.D.
Director
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
lwalter@ucla.edu
Participating Sites
- Aegis Medical Systems, Inc., California
- Robert Wood Johnson University Hospital, New Jersey
- Addiction Research and Treatment Corporation, New York
- Bellevue Hospital Center, New York
- Midtown Community Mental Health Center (under Health & Hospital Corporation of Marion County), Ohio
- Kaiser Permanente, Department of Addiction Medicine